Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

F77 antigen is a promising target for adoptive T cell therapy of prostate cancer

Biochemical and Biophysical Research Communications(2023)10.1016/j.bbrc.2023.09.018Source: DataRank Database

F77 antigen is a promising target for adoptive T cell therapy of prostate cancer is a research paper published in Biochemical and Biophysical Research Communications (2023). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

nct pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.81)OA: hybridTopics (48)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Selene Nuñez-Cruz,John Leferovich,Tyra Wentz ORCID,Atrish Bagchi,Michael C. Milone ORCID

Live enrichment

PubMed:37717341 PMC:PMC10591779 OpenAlex:https://openalex.org/W4386649336

National Cancer Institute

Grant: U54CA244711

National Institutes of Health

Grant: R01CA219034

National Institutes of Health

Grant: R21AI35359

University of Pennsylvania

FWCI

0.81

Citation Percentile

0.7%

Citation Trend

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.bbrc.2023.09.018

publisherhttps://doi.org/10.1016/j.bbrc.2023.09.018

publisherhttps://api.elsevier.com/content/article/PII:S0006291X23010483?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0006291X23010483?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37717341

Fields of Study

CAR-T cell therapy researchImmunotherapy and Immune ResponsesImmune Cell Function and InteractionMaleAnimalsMiceHumansAndrogensCell Line, TumorProstatic NeoplasmsImmunotherapy, AdoptiveCarbohydratesCell- and Tissue-Based TherapyReceptors, Antigen, T-CellXenograft Model Antitumor Assays

MeSH Terms

AndrogensAnimalsCarbohydratesHumansMaleProstatic NeoplasmsReceptors, Antigen, T-CellImmunotherapy, AdoptiveXenograft Model Antitumor AssaysCell Line, TumorMiceCell- and Tissue-Based Therapy

Keywords

Prostate cancerCD137Chimeric antigen receptorImmunotherapyAntigenCancer researchAdoptive cell transferCancerMonoclonal antibodyImmunologyCancer immunotherapyMedicineProstateProstate-specific antigenT cellAntibodyImmune systemInternal medicineCar T TherapyGlycan TherapyF77

Sustainable Development Goals

SDG 0: Good health and well-being

F77 antigen is a promising target for adoptive T cell therapy of prostate cancer

FAIR Checklist

Authors (7)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)